Literature DB >> 2783971

Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS.

W Lang1, H Perkins, R E Anderson, R Royce, N Jewell, W Winkelstein.   

Abstract

CD4 and CD8 T lymphocytes of three groups of men infected by the human immunodeficiency virus (HIV) were examined twice yearly for 36 months to elucidate the temporal trends in T lymphocytes during infection. The three groups were 37 HIV seroconverters, 304 prevalent HIV seropositives remaining free of the acquired immunodeficiency syndrome (AIDS), and 69 men who developed AIDS during observation. Six months before seroconversion, CD4 levels were similar among HIV seroconverters and 356 seronegative controls. Within 18 months of seroconversion, mean CD4 levels fell to the level of the prevalent seropositives at study entry. From there, the rate of decline slowed. CD8 lymphocyte counts rose dramatically at seroconversion. Among AIDS-free prevalent seropositives, CD4 levels fell steadily over 36 months of observation. By contrast, CD8 cell levels rose slowly. Among men who developed AIDS, mean CD4 levels fell more rapidly again during the 18 months prior to diagnosis. CD8 cell levels remained elevated until 6-12 months before diagnosis, when they began to fall.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783971

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  49 in total

1.  A simple relationship between viral load and survival time in HIV-1 infection.

Authors:  R A Arnaout; A L Lloyd; T R O'Brien; J J Goedert; J M Leonard; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults. Site Investigators and The NIAID DAIDS New Technologies Evaluation Group.

Authors:  C T Schnizlein-Bick; J Spritzler; C L Wilkening; J K Nicholson; M R O'Gorman
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

3.  When should asymptomatic patients with HIV infection be treated with zidovudine?

Authors:  B G Gazzard
Journal:  BMJ       Date:  1992-02-22

4.  Capacity of US labs to provide TLI in support of early HIV-1 intervention.

Authors:  R O Valdiserri; G D Cross; A R Gerber; R E Schwartz; T L Hearn
Journal:  Am J Public Health       Date:  1991-04       Impact factor: 9.308

5.  CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Authors:  C E Mackewicz; H W Ortega; J A Levy
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

Review 6.  Lymphocyte subsets as surrogate markers in antiretroviral therapy.

Authors:  J R Bogner; F D Goebel
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 7.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

8.  Opportunities for earlier HIV diagnosis in a pediatric ED.

Authors:  Michelle D Eckerle; Madjimbaye Namde; Carolyn K Holland; Andrew H Ruffner; Kim W Hart; Christopher J Lindsell; Jennifer L Reed; Michael S Lyons
Journal:  Am J Emerg Med       Date:  2015-04-10       Impact factor: 2.469

9.  Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity.

Authors:  K C Watret; J A Whitelaw; K S Froebel; A G Bird
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

10.  Alterations in Serum Zinc and Polyunsaturated Fatty Acid Concentrations in Treatment-Naive HIV-Diagnosed Alcohol-Dependent Subjects with Liver Injury.

Authors:  Vatsalya Vatsalya; Matthew C Cave; Rajarshi Kumar; Shweta Srivastava; Sujita Khanal; Alfred B Jenson; Melanie L Schwandt; Shirish S Barve; Vijay A Ramchandani; Craig J McClain
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-11       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.